KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

John F R Robertson, Zhimin Shao, Shinzaburo Noguchi, Igor Bondarenko, Lawrence Panasci, Sandeep Singh, Shankar Subramaniam, Matthew J Ellis

J Clin Oncol 43(13) 1539-1545

PMID39772884
PMCIDPMC12054979
DOI10.1200/JCO.24.00994
发表日期2025-01-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

The randomized phase III FALCON trial demonstrated significant improvement in progression-free survival (PFS) with fulvestrant versus anastrozole in postmenopausal women with endocrine therapy-naïve, hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Herein, the prespecified final overall survival (OS) analysis is reported. After the primary PFS analysis, data were collected on survival, serious adverse events, and health-related quality of life. The final OS analysis was triggered at ≥65% maturity and ≥8 years since the last patient was enrolled. Analyses were descriptive with nominal P values (one-sided α threshold .01845). At the data cutoff (July 11, 2022), 314 (68.0%) of 462 patients had died (fulvestrant, 157/230 [68.3%], anastrozole, 157/232 [67.7%]). The final OS analysis of FALCON demonstrated no significant difference between fulvestrant and anastrozole (medians, 44.8 and 42.7 months, respectively; hazard ratio [HR], 0.97 [95% CI, 0.77 to 1.21]; P = .7579). Among patients with nonvisceral disease (n = 208), a trend showed a 15% reduction in the relative risk of death with fulvestrant versus anastrozole (median OS, 65.2 v 47.8 months; HR, 0.85 [95% CI, 0.60 to 1.20]). Data from FALCON are consistent with published evidence of long-term clinical benefit with fulvestrant and other endocrine therapies in the subset of patients with nonvisceral disease.

KM 提取结果

2 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure1 个面板

FIG 1.

FIG 1. Kaplan-Meier curve for OS in the ITT population. a HR (fulvestrant:anastrozole) <1 favors fulvestrant. Crosses represent censored observations. HR, hazard ratio; ITT, intention-to-treat; mOS, median OS; OS, overall survival. b Two-sided P value.

OS_in_the_ITT_population

overall survival

FIG 1. · Panel OS_in_the_ITT_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel OS_in_the_ITT_population 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

FIG 2.

FIG 2. OS in patients with (A) nonvisceral or (B) visceral disease a and exploratory analysis in patients with nonvisceral and visceral disease a in the (C) fulvestrant and (D) anastrozole arms. a Visceral disease was defined by the presence of tumors in the adrenal glands, bladder, CNS, esophagus, liver, lung, peritoneum, pleura, kidney, small bowel, stomach, pancreas, thyroid, colon, rectum, ovary, biliary tract, or spleen or by the presence of ascites, or pericardial or pleural effusion. b HR (fulvestrant:anastrozole) <1 favors fulvestrant. Crosses represent censored observations. Data cutoff: July 11, 2022. HR, hazard ratio; mOS, median OS; OS, overall survival.

A

OS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

FIG 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

FIG 2. · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果